Over the next few years, some of the best-known biologic medicines will lose patent protection, paving the way for biosimilar medicines to enter the UK market. This article discusses some innovative IP strategies which may be available in the United Kingdom to successfully compete and overcome barriers to market entry.
Biologic and biosimilar medicines Biosimilars are medicines that seek to compete with, and are similar to, originator biologic products. Biologics contain active substances that are derived from biological sources and are often large, complex molecules such as antibodies.
Biologics are some of the most profitable and widely prescribed medicines. As an example, Adalimumab (Humira), which is used to treat various conditions including rheumatoid arthritis and Crohn s disease, is currently the world s best-selling prescription drug. It is therefore unsurprising that the biosimilars market is highly competitive and is expected to experience substantial growth in the co
Ulcerative Colitis Market Scenario 2020 – Current Trends, Size, Share and Future Opportunities by 2026
Global Ulcerative Colitis Market – Insights
Ulcerative colitis (UC), also known as colitis ulcerosa, is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. It is characterized by diarrhea, sudden and unexplained weight loss, loss of appetite, belly pain/cramps, bleeding from the rectum, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The inflammation results in development of tiny sores known as ulcers. Although the exact cause for UC is not known, probable factors include, genetic aspects, environmental changes, or weakened immune system. Healthy diet, proper hydration, skipping fatty foods, and limited consumption of high-fiber food can help to prevent UC. Although the incidence of the disease is high among people under 30 years of age, it may